Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
analysis
-
kinetic assay for detection of MAO-A inhibitors in plant extracts using recombinant MAO-A expressed as GST-fusion protein in yesat
analysis
-
on-line immobilized enzyme reactors can be used for the on-line screening of substances for MAO-A and substrate/inhibitor properties
analysis
-
on-line immobilized enzyme reactors can be used for the on-line screening of substrances for MAO-A and substrate/inhibitor properties
analysis
both (R)-(-)- and (S)-(+)-1-(1-[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone are very promising tracers for positron emission tomography of the MAO-A enzyme in brain. The carbon-11-labeling reaction is fairly simple and robust. Yields of more than 1 GBq are routinely obtained and with high specific activity of the final product. The metabolism of (R)-(-)- and (S)-(+)-1-(1-[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone is relatively slow in plasma of living pigs, in contrast to [11C]harmine, which is difficult to detect in plasma at times after 10 min. Parametric maps of [11C](R)-(-)- and (S)-(+)-1-(1-[11C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone binding are qualitatively very comparable to those of [11C]harmine
drug development
dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A2A receptors, may have value in the management of Parkinson's disease, overview
drug development
MAO-A is a target for a series of therapeutically valuable drugs. Thus, selective MAO-A inhibitors are used as antidepressants
drug development
MAO-B is a target for a series of therapeutically valuable drugs. Thus, selective MAO-B inhibitors are used in the treatment of Parkinsons disease
drug development
indole and benzofuran derivatives are promising reversible MAO-B inhibitors with a possible role in the treatment of neurodegenerative diseases such as Parkinsons disease
drug development
active monoamine oxidase inhibitors represent suitable leads for the development of drugs for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression. Monoamine oxidase inhibitors are also of interest for the treatment of prostate cancer, certain types of cardiomyopathies and Alzheimer's disease
medicine
-
ethiology of schizophrenia and affective disorders e.g. Parkinson's disease and epilepsy
medicine
-
target for antidepressant and neuroprotective drugs
medicine
the enzyme is a target for anti-depression drug design
medicine
the enzyme is a valuable target for many neurological disorders
medicine
-
the enzyme is a possible target for therapeutic aproaches for obesity and insulin-resistant states
medicine
the enzyme is a target for antidepressant and neuroprotective drugs
medicine
a significant association is found between the G-allele of 941G/T in MAO-A and attention deficit hyperactivity disorder (ADHD)
medicine
-
aminoguanidine may be useful for treating obesity via its SSAO blocking properties
medicine
an atypical case of Norrie disease, consisting of a patient harboring a large submicroscopic deletion affecting not only the NDP gene but also the MAOA, MAOB, and EFHC2 genes, is described
medicine
association study of MAO-A and frontotemporal dementia which does not support the notion that this gene has a major role in the predisposition to this form of dementia
medicine
boys with the short (three-repeat) variant of the MAO-A gene, who had been maltreated/abused or came from families with poor relations, show significantly higher scores of alcohol-related problems. Both maltreatment and MAO-A genotype may be useful for the understanding of male adolescent alcohol-related problem behaviour
medicine
brain MAO A correlates inversely with the multidimensional personality questionnaire trait measure of aggression (but not with other personality traits)
medicine
DRD4 and MAO-A genes may be involved in aggressive schizophrenic patients
medicine
female patients homozygous for the A-allele of monoamine oxidase B have a significantly faster and more pronounced antidepressant treatment response than AG/GG-carriers. In paroxetine-treated females these differences remain statistically significant. In mirtazapine-treated females homozygous for the A-allele compared to AG/GG-carriers, HAMD-17 scores during the study period are constantly and markedly lower, but not statistically different. In males, no association between the MAOB A644G intron 13 SNP and antidepressant treatment response is detected. The MAOB A644G single nucleotide polymorphism is involved in the outcome of treatment with mirtazapine or paroxetine in females with major depression. If replicated, the MAOB A644G polymorphism could be considered useful for prospective confirmatory pharmacogenetic trials in patients with major depression
medicine
females with low platelet MAO-B activity show an increased risk of alcohol-related problem behaviour in an unfavourable environment
medicine
gender-specific contribution of the more active MAO-A variable number tandem repeat (VNTR) variant to an increased vulnerability for complicated grief as a potential intermediate phenotype of major depression
medicine
high-activity MAO-A genotypes possibly by consecutively decreased serotonin and/or norepinephrine availability negatively influence antidepressant treatment response during the first six weeks of pharmacological treatment in female patients with Major Depression
medicine
individuals with less active MAOA-uVNTR alleles who are under chronic stress may be at increased risk for exhaustion of the hypothalamic-pituitary-adrenal response to such stress
medicine
interaction between the norepinephrine transporter and monoamine oxidase A polymorphisms, and novelty-seeking personality traits in Korean females
medicine
MAO B is a stable trait marker for alcoholism. The associations obtained between platelet MAO B activity with executive neurocognitive task and hostility component may support the involvement of plateletMAOB activity in the further development of an impulsive cognitive style
medicine
MAOA deficiency is associated with increased sleep apnea in mice and suggest that an acute or chronic excess of serotonin contributes to this phenotype
medicine
MAOA genotype and cerebrospinal fluid testosterone interact to predict antisocial behaviors
medicine
MAOA polymorphisms do not play a major role in pathogenesis of bipolar disorder or its clinical subtypes in Han Chinese
medicine
MAOA-dependent metabolism of the biological amines may be partly related to high-activated MAO-A, allele 3, in the occurrence of fibromyalgia syndrome among Turkish population
medicine
MAOA-L (the low-expressing allele of the MAOA u-variable-number tandem repeat), by causing an ontogenic excess of 5-hydroxytryptamine, labilizes critical neural circuitry for social evaluation and emotion regulation, thereby amplifying the effects of adverse early-life experience and creating deleterious sociocognitive biases
medicine
methylation of the MAOA promoter is associated with nicotine dependence and alcohol dependence in females
medicine
monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder
medicine
MPTP-induced apoptosis of neural progenitor cells in the subventricular zone and rostral migratory stream is, at least in part, involved in the mechanism of MAO-B-mediated conversion of MPTP into 1-methyl-4-phenylpyridinium in vivo
medicine
no association among this intergenic haplotype combination and suicidal behaviour in bipolar disorder
medicine
no difference in allelic distributions of two MAOA polymorphisms is found, the risk haplotype 114S is associated with bipolar affective disorder in male patients. The significance is not found in female patients with 114S haplotype. MAOA may have a gender-specific and small effect on the etiology of bipolar affective disorder in Taiwan
medicine
no evidence for interaction between MAOA and childhood adversity for antisocial behavior
medicine
no significant evidence of association between the variable number tandem repeat and T941G polymorphisms and schizophrenia
medicine
non-selective MAO and selective MAO-A inhibitors can induce 5-hydroxytryptamine syndrome in humans when co-administered with antidepressants. Furthermore, the risk of 5-hydroxytryptamine syndrome may be lower with the selective MAO-B inhibitor selegiline
medicine
-
platelet MAO activity may be a marker of severity of obsessive-compulsive disorder. Low platelet monoamine oxidase activity may be associated with aggressive obsessions in patients with obsessive-compulsive disorder
medicine
presence of the long (4-repeat) variant of the MAO-A gene in females interacted significantly with an unfavourable environment (poor family relations or maltreatment/abuse/sexual abuse) to increase the risk for high scores of alcohol-related problems
medicine
quantification of MAO-B activity may be a useful diagnostic tool for differentiating glial tumours from other types of brain tumours or surrounding normal brain tissue
medicine
-
selegiline is an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. The selegiline transdermal system provides several advantages compared to orally administered monoamine oxidase inhibitors, including minimal interaction with dietary tyramine and prolonged exposure to the parent compound, while offering a favorable side effect profile. Treatment at the lowest effective dose of 6 mg/24 hours can be administered without the need for dietary modifications
medicine
strongest evidence for the involvement of MAOB gene in the etiology of attention deficit hyperactivity disorder (ADHD), at least in Han Chinese population
medicine
the fibroblast growth factor 20 (FGF20) and monoamine oxidase B (MAOB) genes are associated with Parkinson Disease risk. Variants in FGF20 and MAOB show evidence of statistical interactions, which emphasizes the importance of considering them jointly in genetic analysis of Parkinson Disease
medicine
the in vivo MAO-B inhibiting effect of lamotrigine might contribute in part to its antidepressant activity
medicine
the MAO B inhibitor rasagiline is initiated at 1 mg once-daily dosage as monotherap in early Parkinsons disease patients and at 0.51 mg once-daily as adjunctive to levodopa in advanced Parkinsons disease patients. Rasagiline treatment is not associated with cheese effect and up to 20 mg per day is well tolerated. In Parkinsons disease patients with hepatic impairment, rasagiline dosage should be carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and coadministration with certain antidepressants and opioids should be avoided. This drug provides an additional tool for Parkinsons disease therapy improvement in motor performance
medicine
the MAO B inhibitor selegiline is efficacious in the therapeutic management of Parkinson's disease
medicine
the MAO inhibitor moclobemide is promising in the therapeutic management of post-traumatic stress disorder and panic disorder
medicine
the monoamine oxidase B inhibitor N-propargyl-l(R)-aminoindan (i.e. rasagiline) is well tolerated and effective in the treatment of early Parkinson's disease and as adjunctive treatment in levodopa-treated patients with Parkinson's disease experiencing motor fluctuations
medicine
the monoamine oxidase inhibitor rasagiline may provide a much lower risk of serotonin syndrome than the monoamine oxidase inhibitor selegiline in parkinsonian patients treated with an serotonin reuptake inhibitor
medicine
theoretical and experimental support for the notion that cigarette smokeinduced inhibition of MAO in the fetal brain, particularly when it occurs in combination with polymorphisms in the MAOA gene that lead to lower enzyme concentration in the brain, may result in brain morphologic and functional changes that enhance the risk of irritability, poor self-control and aggression in the offspring
medicine
-
tobacco smoke contains monoamine oxidase inhibitors. Gestational nicotine and monoamine oxidase inhibitors both influence brain development
medicine
when combined with exposure to early traumatic life events, low MAOA activity is a significant risk factor for aggressive behavior during adulthood
medicine
MAO-A is a target for a series of therapeutically valuable drugs. Thus, selective MAO-A inhibitors are used as antidepressants
medicine
MAO-B is a target for a series of therapeutically valuable drugs. Thus, selective MAO-B inhibitorsare used in the treatment of Parkinsons disease
medicine
Rhodiola rosea roots have potent antidepressant activity by inhibiting MAO A and may also find application in the control of senile dementia by their inhibition of MAO B
medicine
monoamine oxidase is an important drug target for the treatment of neurological disorders
synthesis
the enzyme is used to successfully identify the alkaloid (+/-)-crispine A as a target for chemo-enzymatic deracemisation yielding the biologically active (R)-enantiomer in 97% enantiomeric excess
synthesis
monoamine oxidase (MAO-N) is a synthetic tool for the enantioselective synthesis of chiral amines
synthesis
when deracemizing 1,2,3,4-tetrahydro-1-methylisoquinoline on a preparative scale, the MAO-N variant W230R/W430C/C214L allows access to the (S)-enantiomer. It also shows good activity in the preparation of (S)-1,2,3,4-tetrahydro-1-ethylisoquinoline and (S)-1,2,3,4-tetrahydro-1-isopropylisoquinoline on a preparative scale